While there were partial memory enhancing effects of the ARB losartan in APP mutated mice, these effects were ameliorated by selective blockade of angiotensin IV (AngIV) at its receptor (AT4R), implicating the angiotensin IV/AT4R cascade as a promising candidate for AD intervention (Royea et al., 2017). Here, AGT is linked to Alzheimer disease.